array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2518) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(95) "Cullen Frost Bankers Inc. Purchases 101 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(117) "Read Cullen Frost Bankers Inc. Purchases 101 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) at Defense World" ["url"]=> string(133) "http://www.defenseworld.net/2024/09/10/cullen-frost-bankers-inc-purchases-101-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/fe2c4d1f-4cc6-4751-8211-921979dbf212" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2024-09-10" ["categories"]=> array(3) { [0]=> string(12) "Stock Market" [1]=> string(15) "Market Movement" [2]=> string(24) "Stock Research & Ratings" } } [1]=> array(7) { ["title_en"]=> string(115) "RBC Capital remains cautious on Regeneron shares, highlights market potential of Factor XI program By Investing.com" ["snippet_en"]=> string(98) "RBC Capital remains cautious on Regeneron shares, highlights market potential of Factor XI program" ["url"]=> string(166) "https://fr.investing.com/news/company-news/rbc-capital-reste-prudent-sur-les-actions-de-regeneron-souligne-le-potentiel-de-marche-du-programme-facteur-xi-93CH-2556535" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-09-10" ["categories"]=> array(2) { [0]=> string(12) "Stock Market" [1]=> string(15) "Market Movement" } } [2]=> array(7) { ["title_en"]=> string(61) "REGENERON PHARMACEUTICALS News and Stock Quote (NASDAQ: REGN)" ["snippet_en"]=> string(73) "Real-Time News, Market Data and Stock Quote for REGENERON PHARMACEUTICALS" ["url"]=> string(76) "https://greenstocknews.com/market-data/stock-quote/regeneron-pharmaceuticals" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6efd94b3-164a-4e96-a117-d5b2d03cdfc6" ["source"]=> string(18) "greenstocknews.com" ["publication_date"]=> string(10) "2024-08-23" ["categories"]=> array(2) { [0]=> string(12) "Stock Market" [1]=> string(15) "Market Movement" } } [3]=> array(7) { ["title_en"]=> string(147) "Why Regeneron Pharmaceuticals Stock Moved: REGN Stock Has Gained 143% Since 2020 Primarily Due To Favorable Change In Price To Sales Multiple (P/S)" ["snippet_en"]=> string(59) "Why Regeneron Pharmaceuticals (REGN) stock moved since 2020" ["url"]=> string(214) "https://www.trefis.com/data/companies/REGN/no-login-required/QDcKOxXG/Why-Regeneron-Pharmaceuticals-Stock-Moved-REGN-Stock-Has-Gained-139-Since-2020-Primarily-Due-To-Favorable-Change-In-Price-To-Sales-Multiple-P-S-" ["image_url"]=> NULL ["source"]=> string(10) "trefis.com" ["publication_date"]=> string(10) "2024-08-16" ["categories"]=> array(3) { [0]=> string(12) "Stock Market" [1]=> string(15) "Market Movement" [2]=> string(24) "Stock Research & Ratings" } } [4]=> array(7) { ["title_en"]=> string(105) "3 stocks with very high potential (and risk): Intellia Therapeutics, ChargePoint Holdings, Blink Charging" ["snippet_en"]=> string(201) "Today we are going to look at 3 stocks that, in addition to trading below their price based on fundamentals, have a very high market target: Intellia Therapeutics, ChargePoint Holdings, Blink Charging." ["url"]=> string(126) "https://www.megabolsa.com/2024/08/13/potencial-elevadisimo-y-riesgo-intellia-therapeutics-chargepoint-holdings-blink-charging/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/078e63c3-985e-4f14-a898-a87855649101" ["source"]=> string(13) "megabolsa.com" ["publication_date"]=> string(10) "2024-08-13" ["categories"]=> array(5) { [0]=> string(12) "Stock Market" [1]=> string(14) "Product Launch" [2]=> string(13) "Collaboration" [3]=> string(15) "Market Movement" [4]=> string(11) "Competition" } } [5]=> array(7) { ["title_en"]=> string(70) "Skin Cancer Treatment Market Set to Surge to USD 20.74 Billion By 2032" ["snippet_en"]=> string(225) "The Skin Cancer Treatment Market was valued at USD 10.98 billion in 2023 and is expected to reach USD 20.74 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.66% over the forecast period from 2024 to 2032." ["url"]=> string(134) "https://www.whatech.com/og/markets-research/medical/864341-skin-cancer-treatment-market-set-to-surge-to-usd-20-74-billion-by-2032.html" ["image_url"]=> NULL ["source"]=> string(11) "whatech.com" ["publication_date"]=> string(10) "2024-08-08" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(15) "Market Movement" } } [6]=> array(7) { ["title_en"]=> string(86) "Global biosimilar market estimated to reach a size of $43.8 billion by the end of 2024" ["snippet_en"]=> string(199) "Demand for biosimilars is booming, with no hints of slowing down as the number of biosimilars getting approved keeps growing. Here are all the biosimilars that have received approval in 2024 to date." ["url"]=> string(104) "https://www.biopharma-reporter.com/Article/2024/07/24/Trends-in-biosimilars-Regulatory-approvals-in-2024" ["image_url"]=> string(78) "https://images.businessradar.com/articles/e06b653f-2c82-4317-8e59-ccd23accdf40" ["source"]=> string(22) "biopharma-reporter.com" ["publication_date"]=> string(10) "2024-07-24" ["categories"]=> array(1) { [0]=> string(15) "Market Movement" } } [7]=> array(7) { ["title_en"]=> string(58) "Which Stock Market Sectors Perform Better During Recession" ["snippet_en"]=> string(136) "Uncover the sectors that thrive during tough economic times. Gain insight into investment strategies for stability and potential growth." ["url"]=> string(89) "https://theluxuryplaybook.com/which-stock-market-sectors-perform-better-during-recession/" ["image_url"]=> NULL ["source"]=> string(21) "theluxuryplaybook.com" ["publication_date"]=> string(10) "2024-06-19" ["categories"]=> array(5) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(18) "General Investment" [2]=> string(24) "Quarterly/Annual Figures" [3]=> string(12) "Stock Market" [4]=> string(15) "Market Movement" } } [8]=> array(7) { ["title_en"]=> string(119) "RBC raises stock price target for Regeneron stock to $1,229 on back of higher Dupixent sales estimates By Investing.com" ["snippet_en"]=> string(111) "RBC raised its stock price target for Regeneron stock to $1,229 on the back of higher Dupixent sales estimates." ["url"]=> string(63) "https://sa.investing.com/news/company-news/article-93CH-2597002" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-06-14" ["categories"]=> array(3) { [0]=> string(12) "Stock Market" [1]=> string(15) "Market Movement" [2]=> string(24) "Stock Research & Ratings" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(219) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(195) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(163) } [3]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(111) } [4]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(109) } [5]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(104) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(90) } [7]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(65) } [8]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(54) } [9]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(52) } [10]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(52) } [11]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(49) } [12]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(48) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(41) } [14]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(39) } [15]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(36) } [16]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(35) } [17]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(34) } [18]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(32) } [19]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(31) } [20]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(31) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(31) } [22]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(30) } [23]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(29) } [24]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [25]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(27) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(23) } [28]=> array(2) { ["name"]=> string(8) "Politics" ["count"]=> int(19) } [29]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(19) } } } c469a-us-regeneron-pharmaceuticals-inc